|Bid||94.57 x 4000|
|Ask||94.58 x 900|
|Day's Range||94.39 - 94.77|
|52 Week Range||77.04 - 98.52|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||27.19|
|Forward Dividend & Yield||3.20 (3.41%)|
|Ex-Dividend Date||Mar. 04, 2021|
|1y Target Est||105.13|
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal nocturnal hemoglobinuria (PNH) patients1New results are promising for potential use of iptacopan as monotherapy in PNH, a rare and life-threatening blood disorder2,3; results from a previous Phase II study showed iptacopan substantially improved hematological response as add-on to standard-of-care (ecul